United Health Products Inc (UEEC)

[shoondale]

DR5
Re: AnyDayNowX post# 12897
Friday, January 19, 2024 11:45:25 AM
Post# 12899 of 13036
"Confirmation of submission should come next week".

"On 12/4/17, UEEC issued a PR stating:

it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program.

Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review"

https://seekingalpha.com/article/4300303-united-health-products-press-releases-cannot-be-taken-face-value
Replace CtQ with estar for the newest bullshit con game. It's just regurgitated bullshit. Anyone who thinks this will pass Class III after not hearing a damn thing about Class II from 7 years ago quite frankly is an idiot. If sterilization and packaging are a problem, Johnson & Johnson could have subcontracted - they have been packing sterile gauze since the year 1900. Anyone still think this Ponzi Scheme is genuine?

United Health Products Reports on FDA Application Status
United Health Products, Inc.
January 19, 2024·2 min read
In this article:

UEEC
-4.42%
Watchlist

Watchlist
MESQUITE, NV, Jan. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – United Health Products (UEEC) reports today on the receipt and review of final reports on product sterilization and stability testing for its hemostatic gauze. As previously disclosed, UHP has been working with external packaging and sterilization service providers to complete various required tests for its Premarket Approval application. The reported data received this week on the efficacy of the proposed radiation sterilization protocol were well within acceptable bioburden levels for Class III products. UHP will now compile these data and proceed with final drafting of the PMA documentation to be submitted via the eSTAR platform for FDA and Health Canada review.

There can be no assurance that the company’s PMA or Health Canada applications will be approved.

About United Health Products -- UHP develops, manufactures and markets HemoStyp™, a patented Neutralized Regenerated Cellulose hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and emergency medicine markets, and is seeking approval to access the human surgical market.

For more information on UHP visit the company’s new website: www.uhpcorp.com or contact the company at [e-mail].

The company can also be reached by phone or text message at 475.755.1005.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

https://finance.yahoo.com/news/united-health-products-reports-fda-133200145.html